NCT05081492
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have progressed on or been intolerant of at least 2 prior lines of therapy for advanced/metastatic disease; Patients that qualify for immunotherapy and/or PARP inhibitors must have progressed on or been intolerant of these agents
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05081492